Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer 

Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer 

The application of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) has significantly improved the survival of patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, there are still a portion of patients with poor efficacy and prognosis. Therefore, it is urgent...

Full description

Bibliographic Details
Main Author: HE Xi, JIAO Xiaodong, ZANG Yuansheng
Format: Article
Language:English
Published: Editorial Office of China Oncology 2021-01-01
Series:Zhongguo aizheng zazhi
Subjects:
non-small cell lung cancer| tumor mutational burden|epidermal growth factor receptor|next-generation sequencing|comprehensive genomic profiling| prognosis
Online Access:http://www.china-oncology.com/fileup/1007-3639/PDF/20210109.pdf

Internet

http://www.china-oncology.com/fileup/1007-3639/PDF/20210109.pdf

Similar Items